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Abstract: Prior to its total synthesis, a new vanadium coordination compound, called TSAG0101, 
was computationally designed to inhibit the enzyme protein tyrosine phosphatase 1B (PTP1B). 
The PTP1B acts as a negative regulator of insulin signaling by blocking the active site where 
phosphate hydrolysis of the insulin receptor takes place. TSAG001, [VVO
2
(OH)(picolinamide)], 
was characterized by infrared (IR) and nuclear magnetic resonance (NMR) spectroscopy; 
IR: ν/cm−1 3,570 (NH), 1,627 (C=O, coordinated), 1,417 (C−N), 970/842 (O=V=O), 727 δ. 
(pyridine ring); 13C NMR: 5 bands between 122 and 151 ppm and carbonyl C shifted to 180 
ppm; and 1H NMR: 4 broad bands from 7.6 to 8.2 ppm and NH
2
 shifted to 8.8 ppm. In aque-
ous solution, in presence or absence of sodium citrate as a biologically relevant and ubiquitous 
chelator, TSAG0101 undergoes neither ligand exchange nor reduction of its central vanadium 
atom during 24 hours. TSAG0101 shows blood glucose lowering effects in rats but it produced 
no alteration of basal- or glucose-induced insulin secretion on β cells during in vitro tests, all 
of which excludes a direct mechanism evidencing the extrapancreatic nature of its activity. The 
lethal dose (LD
50
) of TSAG0101 was determined in Wistar mice yielding a value of 412 mg/kg. 
This value is one of the highest among vanadium compounds and classifies it as a mild toxic-
ity agent when compared with literature data. Due to its nonsubstituted, small-sized scaffold 
design, its remarkable complex stability, and low toxicity; TSAG0101 should be considered as 
an innovative insulin-mimetic principle with promising properties and, therefore, could become 
a new lead compound for potential nonpeptide PTP1B inhibitors in antidiabetic drug research. 
In view of the present work, the inhibitory concentration (IC
50
) and extended solution stability 
will be tested.
Keywords: inhibitors, PTP1B, computer assisted drug design (CADD), insulin, diabetes
Introduction
There are 2 clinical forms of diabetes mellitus.1 Type 1 (or juvenile) diabetes is primar-
ily due to autoimmune-mediated destruction of pancreatic β-cell islets, resulting in an 
absolute insulin deficiency. Patients with type 1 diabetes depend on a daily exogenous 
insulin administration (IM) to prevent the development of ketoacidosis. Its frequency 
is low when compared to that of type 2 diabetes, which accounts for over 90% of 
all reported cases worldwide. Type 2 diabetes is characterized by insulin resistance 
(peripheral or extrapancreatic) and/or abnormal insulin secretion (pancreatic), either of 
which may predominate. At the beginning, type 2 patients do not depend on exogenous 
insulin uptake, but may require it for controlling blood glucose levels if this cannot be 
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achieved with diet alone or combined with oral hypoglycemic 
agents. Changes in living conditions, habits, and lifestyle over 
the last century have led not only to a  dramatic increase in 
life span but also to the incidence of type 2 diabetes known 
as “diabesity”2 or “metabolic syndrome.”3 In conjunction with 
genetic susceptibility, particularly in certain ethnic groups, 
type 2 diabetes is caused by environmental and behavioral 
factors such as sedentary lifestyle, overly rich nutrition, and 
obesity. The prevention of diabetes and control of its micro- 
and macrovascular complications will require an integrated 
approach for the significant reduction in the huge premature 
morbidity and mortality it causes.4
Current therapeutic approaches have largely been devel-
oped in the absence of defined molecular targets or even 
a solid understanding of disease pathogenesis. Within the 
recent past, our understanding of biochemical pathways 
related to the development of metabolic syndrome has 
expanded. Now, there is a steady growing range of molecular 
drug targets within these pathways. They are identified on the 
basis of predicted roles in modulating one or more key aspects 
of the pathogenesis of diabetes or metabolic syndrome. Sev-
eral mechanistic categories for new therapeutic approaches 
can be considered. In a key position are approaches aimed at 
reducing excessive glucose production by the liver, besides 
mechanisms to augment glucose-stimulated insulin secretion, 
specific molecular targets in the insulin signaling pathway, 
and new approaches to obesity and altered lipid metabolism, 
which offer the prospect of net improvements in insulin 
action (or secretion).5
The insulin signaling pathway starts with the binding of 
insulin to the extracellular α subunit of the transmembranal 
insulin receptor leading to a conformational change in the 
intracellular β subunit and promotion of the autophos-
phorylation at a number of tyrosine residues, Y + P = PY 
(Figure 1). Although the receptor protein tyrosine kinase is 
a positive regulator of the signal transduction, the protein 
tyrosine phosphatase (PTP) represents a negative one. The 
insulin receptor itself acts as a tyrosine kinase by transferring 
Lipid bilayer
RPTK
PTP
V
V
V
V
P/PY PY
Insulin
β sub-unit
α sub-unit
Glucose
GLUT4
PY-prot
Insulin cascade
Y-prot
SRI-1
PY-prot
Cyt-PTK
Y-prot
Figure 1 Schematic display of potential biomolecular targets of vanadium compounds within the human cell. The metabolic pathway of the insulin cascade is depicted. A double 
line symbolizes the cellular membrane, with the extracellular part above and the intracellular part below.
Abbreviations: Letter V, possible vanadium target; P/PY, tyrosine residue phosporilated/nonphosphorylated; rPTK, receptor protein tyrosine kinase (positive regulator); PTP, 
protein tyrosine phosphatase (negative regulator); Y-prot, nonphosphorylated cytosolic protein; PY-prot, phosphorylated cytosolic protein; Sri-1, substrate 1 for the insulin 
receptor; cyt-PTK, cytosolic protein tyrosine kinase.
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phosphate to different receptor substrates, especially insulin 
receptor substrate 1, which in turn propagates the insulin sig-
naling through phosphate transfer to cytoplasmatic proteins 
(Y-prot), and all the metabolic effects further downstream. 
In the process, insulin increases glucose transport in fat 
and muscle cells by stimulating the translocation of the 
transporter GLUT4 from intracellular sites to the plasma 
membrane and thereby promoting its exocytosis.6
Among the hitherto known PTPs, protein tyrosine phos-
phatase 1B (PTP1B) has received much attention due to its 
role as a negative regulator of insulin signaling.7,8 Clearly, 
a selective control of the biological function of PTP1B is a 
challenging task, and an inhibitor must not only efficiently 
bind to the specific target enzyme but also do so without 
impeding the catalytic behavior of closely related enzymes. 
The design of small molecule PTP1B inhibitors to treat type 
2 diabetes has received considerable attention.9–15
Since the early discovery of the insulin-like activity of van-
adate,16,17 VO
4
−3, vanadium salts have kept their rank among 
the highest inhibitory activities against PTP,8,18 although not 
in a selective manner. Other targets for monomeric vanadate 
or vanadyl are adenosine triphosphatases, adenyl cyclases, 
and calcium channels,19 and F-actin in the case of decava-
nadate (V
10
).20 Nevertheless, the insulin-like activities of a 
number of vanadium coordination compounds have been 
well documented.17,21–23 Some of their effects were found as 
enhancement of glucose uptake, biosynthesis of glycogen, 
as well as inhibition of gluconeogenesis or lipolysis.24,25 The 
molecular action mechanism of vanadate and the vanadium 
complexes has not yet been sufficiently established.  However, 
after different studies, it is accepted now that vanadium tar-
gets may be protein phosphatases,26,18,27–30 instead of insulin 
hormone itself or insulin receptors GLUT2 and GLUT4 
messengers.31 Recently, literature evidence appears in support 
of the hypothesis that active vanadium compounds may have 
intrinsic affinity to the PTP1B catalytic site.32–35
The insulin-like properties of vanadium have been dem-
onstrated in a conclusive way based on in vitro experiments,36 
in vivo assays in rats37,38 or mice,39 as well as in patients with 
diabetes.40 It is noteworthy to state that as yet all clinical stud-
ies have been carried out successfully using inorganic salts of 
vanadium, albeit it is beyond doubt that the true potential lies 
in the use of organic vanadium complexes, judging from the 
higher activity and the lower toxicity rates.41–43 In  addition, 
vanadium insulin-mimetic effects are superior to other heavy 
metals (Cr, Zn, and Cd),44,45 since vanadium research seeks to 
strengthen therapeutic benefits over toxicities.46,47  Especially 
vanadium seems not to present negative  accumulation 
effects.48 Our present study also aims at the ongoing  discussion 
on the prodrug role of vanadium coordination compounds 
(stability against ubiquitous citrate).46 Different research 
teams have developed new organic compounds of vanadium 
to improve the drug properties. In the present work, due to 
the reported identification of a biomolecular target we could 
devise a so-called de novo design procedure. In a previous 
work,35 we demonstrated that vanadium compounds stated 
in the literature as the most active antidiabetics are also 
potential PTP1B inhibitors.35 Particularly, in the case of 
bis(maltolate) oxo-vanadium(IV) (BMOV) and ammonium 
bis(picolinate) oxo-vanadium(V), we determined the active 
conformations during simulated docking into the target 
enzyme (PTP1B).35,49
In the present work, we report the design, synthesis, 
bioassays, and toxicity tests for a new organic vanadium 
compound (TSAG0101).
Methods
De novo design
Vanadium complexes were designed by a chimeric procedure 
of combinatory chemistry to obtain organic oxo-vanadium 
complexes of type VO
2
L where V is the central vanadium 
atom and L stands for ligand. The former imitates the geom-
etry of a phosphate anion, phosphatomimetic group,46 whereas 
the latter is composed of unrelated organic rests (strong chelat-
ing groups). To this end, pharmacologically and chemically 
known molecular fragments (A, B, and Q in Figure 2) were 
combined to build an imaginary compound using Chem3D of 
the ChemOffice 5.0 tool box.50 Each building block (fragment) 
follows a specific structural pattern and function:
1. Quelate fragment (Q): coordinates the dioxovanadate 
ion, VO2+ and interacts with the Cys215 from the PTP1B. 
Furthermore, these molecular fragments have aromatic 
interaction with residues Phe182 and Tyr46.
2. Basic fragment (B): interacts with the acid residue 
Asp181, at the center of the PTP1B cavity.
3. Acidic fragment (A): allows the molecular recognition 
of the substrate by the external PTP1B residues Arg45 
and Arg47.
geometry optimization  
of designed complexes
Density functional theory (DFT) with B3LYP hybrid 
exchange – correlation functional is a well-accepted stan-
dard procedure in computing of the equilibrium geometry. 
 Especially, DFT/B3LYP is used for molecular geometry 
optimization of ligands. The basis set for all atoms is 
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6–31 + G(d,p). A frequency computation is carried out using 
the optimized structures to provide a complete description 
of the  molecular motions in normal mode. The absence of 
the imaginary frequencies after diagonalization of Hessian 
matrix confirmed that the optimized structure is the real 
minima on the ground state hyperdimensional surface. By 
means of visual inspection using the Gaussview program, 
the modes can be assigned to the irreducible representations 
of the point groups. All calculations have been done using 
Gaussian03 program suite,51 and Gaussview V3.0952 has been 
used for visualizing the conformers.
Modeling of the interaction PTP1B 
(receptor) – vanadium complexes (ligand)
Prior to manual ligand docking at the active site of the crystal 
structure53 (PDB-code: 2HNP) of PTP1B,54 the Tripos force 
field in Sybyl55 was adapted for computing the steric and 
electrostatic energetics of ligand–receptor complex relax-
ations. In addition, modeling software packages MOE,56 
Hyperchem,57 and ChemAxon58 were used during consecutive 
stages of the work and at different places (see Acknowledg-
ments) with the methods reported elsewhere.35 In particular, 
chimeric candidates were fitted into the pharmacophore 
model based on intuitive grounds (guessing conformational 
entropy effects, hydrophobic burial, π-stacking, etc). Particu-
larly, sensitive aspects of ligand docking like reliability and 
model limitations as well as target flexibility were considered 
and taken from the expert literature.59–61
Synthesis of VO2L complexes
The synthesis of VO
2
L complexes was accomplished with 
the triethyl ester of vanadic acid, VO(OEt)
3
. For its in situ 
preparation, a procedure was adapted from literature.62 Finely 
grounded V
2
O
5
(s) was refluxed in absolute ethanol overnight, 
the ethanol was previously treated with molecular sieve. The 
resultant olive green-colored slurry was cooled to room tem-
perature and then filtered through a tared fritted glass filter to 
yield a clear, pale yellow solution of VO(OEt)
3
. The filtered 
B
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Figure 2 Molecular subunits used for the chimeric procedure. The design scheme allows the insertion of 2 or 3 fragments.
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solid was dried by air flux, and its mass was determined every 
hour until constant weight. Yield of VO(OEt)
3
 was calcu-
lated from the difference in the initial and recovered masses 
of V
2
O
5
, assuming that the recovered solid was unreacted 
V
2
O
5
. Previously prepared solution of VO(OEt)
3
 (filtered 
eventually) was stirred at room  temperature. The ligand was 
added very slowly (stoichiometry 1:1) and dissolved in the 
minimum of ethanol. After ligand addition, there was a color 
change in the solution from pale green-yellow to a bright 
clear yellow. The resulting reaction mixture was stirred at 
room temperature for 1 hour after the addition of the ligand. 
Volume was reduced by half or until the appearance of solid, 
using a rotary evaporator with vacuum pump. At this point, 
the solution was put aside for slow crystallization by evapora-
tion at room temperature, until the product had precipitated 
completely. Reaction mixture was decanted and ethanol 
was added to the slurry to double the volume. Ethanol was 
previously treated with a molecular sieve. The solid was 
washed vigorously with the ethanol and then put aside for 
precipitation, after the complete precipitation the mixture was 
decanted, these washes were done until the  supernatant was 
not colored and a final wash was performed with a mixture 
80:20 ethanol:acetone. Solution was decanted and the slurry 
was dried in a vial under vacuum. Spectroscopy character-
ization was done by infrared (IR [KBr]), 1H and 13C nuclear 
magnetic resonance (NMR) in deuterated water.
Solution stability of VO2L complexes
For the solution stability tests, 2 solutions were prepared: one 
is vanadium compound in a concentration of 2.5 × 10−4 M, 
physiological pH 7.4 and the other one containing sodium 
citrate 1:1, which is a natural reducing and chelating agent 
for vanadium. The solutions were used for experiments of 
accumulation of spectra carried out for 27 hours.
Pancreatic activity of VO2L complexes
Inbred, female Lewis rats (200 g) were purchased from Charles 
River (Sulzfeld, Germany). Islets were isolated by collagenase 
digestion63 and purified by handpicking under the binocular. 
Batches of 5 freshly isolated islets were incubated in 1 mL of 
medium for 1 hour at 37°C. The incubation medium consisted 
of (mM) Na+, 122; K+, 4.7; Ca2+, 2.5; Mg2+, 1; Hepes, 10. The 
medium was supplemented with albumin (0.5%) and glucose. 
The pH was adjusted to 7.4 with NaOH. The test substance 
was dissolved in glucose-free incubation medium. Batches of 5 
freshly isolated islets were incubated in 1 mL of incubation buf-
fer for 1 hour at 37°C. After 1 hour of incubation, the samples 
were rapidly cooled on ice and an aliquot of medium was saved 
for insulin determination. The insulin content of each sample 
was analyzed in duplicate by enzyme-linked immunosorbent 
assay (Mercodia AB, Sweden) and the duplicate mean was 
entered as one observation. Values are means + standard devia-
tion observed in 3 independent islet preparations.
LD50 test of VO2L complexes
The following lists the main facts of the lethal dose (LD
50
) 
test in an order that follows the procedure:
Test substances
vanadium complex synthesized in this work; ammonium 
vanadate, NH
4
VO
3
, as reference.
Method
Oral Acute Toxicity Up-And-Down-Procedure, published by 
the Organization for Economic Cooperation and Develop-
ment (OECD), in the document: “Guideline for the Testing 
of Chemicals, SECTION 4: Health Effects Test No. 425, Oral 
Acute Toxicity: Up-and-Down Procedure.”64
Software
Oral Acute Toxicity Statistical Program (Guideline 425; 
AOT425StatPgm).65
Animal model: 15 mice for substance, provided by the 
Bioterio “Claude Bernard,” BUAP.
Administration
intragastric, dose according to program, diluted in 2 cm3 of 
solution of NaCl 0.3%.
Procedure
According to the OECD “Guideline for the Testing of Chemi-
cals,”65 with a preliminary value of 175 mg/kg and a factor of 
progression of dose of 3.2 for NH
4
VO
3
. In the case of the tested 
vanadium compound, the reference value of LD
50
 was that of 
the compound BMOV, 220 mg/kg.66 Test consists of the dos-
age of the animals, one at a time, in intervals of 48 hours. The 
first animal receives a dose a step behind from the reference 
value of LD
50
. If the animal survives, the dose for the following 
animal is increased by an adaptor factor of dose progression 
(default, 3.2 times). Dosification tree is shown in Scheme 1. 
Each animal should be observed carefully for 48 hours, before 
making a decision about its short-term survival. All animals are 
kept under observation for 14 days in total, to establish their 
long-term survival. The survival data in the short run for each 
animal are registered in the software AOT425StatPgm, and the 
program assesses the next dose until the program recognizes 
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1 of the 3 preestablished situations to stop the calculation 
loop. Once the dose assessment has been stalled, the results 
of long-term test data (14 days) are registered in the program. 
The animals were killed to end their suffering by humanitar-
ian means before the end of the observation period, and were 
counted as dead. The LD
50
 values are calculated according to 
the statistical method of maximum probability.67,68
Results and discussion
computer assisted drug design
In the first stage of the drug design study, the modeler of the 
group (TS) previously devised a pharmacophore model based 
on PTP1B inhibitors9–15 in collaboration and documented in 
a graduate thesis.49 Then, few suitable vanadium complexes 
(ligands) were created for the chimeric procedure described 
earlier. The geometries were optimized by Gaussian 03. 
A docking procedure inside the cavity was performed to 
accommodate the ligand in the best position. A criterion 
was established to look for the best binders and docked 
positions inside the active site: during manual docking, all 
those chimeric combinations with large repulsion due to 
steric hindrance were discarded. From the literature, certain 
experimental findings were taken into account to improve the 
final pharmacophore models: planar sandwich or face-to-face 
parallel-stacked geometry under an attractive charge-transfer 
interaction between aromatic systems showing electron-
deficiency and electron-rich areas, with an energy gain of 
1.5 kcal/mol at a distance between ring centers 5 nm.69 Similar 
observations were made by Gung et al70: ∆H of −2 kcal/mol 
and a ∆S of −3 kcal/mol. Especially, π-stacking with edge-
to-face (T-shaped), also OH–π arrangements, cation–π 
interactions, and Coulombic enzyme–substrate interactions 
are reported by Meyer et al.71 An empirical study observed 
that the aromatic side chains of amino acids prefer an off-
centered parallel alignment in proteins (parallel displaced 
π-stacking).72 Moreover,  calculations show that organic-
cationic compounds interact with π bonds very strongly 
(10–22 kcal/mol−1), and are even more stable than ion-pair 
interactions, like salt bridges between tetra-alkylammonium 
ions and anionic residues in aqueous solution. This is an 
important finding for molecular recognition by cation–π 
interactions.73
As a final result, a small-sized nonsubstituted vanadium 
compound, TSAG0101, constitutes a potential lead compound 
to build a novel series of insulin-mimetic drug candidates. Fig-
ure 3 displays the receptor–ligand complexes for the chimeric 
A B
Figure 3 A) Superposition of peptidic inhibitors found in crystal complexes (PDB 
codes: 1BZh, 1BZc, 1PTU, 1c83, 2hnP, and 2hnQ) with their common target 
PTP1B. This model helps (1) to visualize structural diversity and similarities to define a 
consensus pharmacophore pattern regarding volume, shape, polar/nonpolar, and basic/
acidic fields, (2) to identify interacting amino acids at the binding site, and (3) to identify 
unoccupied pockets, and finally estimate conformational entropic effects upon binding. 
b) Final active site poses of the chimeric series (TSAg0101, TSAg0203, TSAg0302, 
TSAg0701, TSAg0702, TSAg0703, and TSAg0704) after manual docking.
O
70
Preliminary estimate value LD50 > 220
Sigma estimate: 0.5 (slope for dose–response plot)
Experimental substance: TSAG0101
Preliminary estimate value LD50 175 mg/kg
Sigma estimate: 0.5 (slope for dose–response plot)
Experimental substance: NH4VO3
220 22
700 70 70 7
O O
X
X X
O
175
550 55
2000 175 175 17.5
O O
X
X X
Scheme 1 Dosification tree for the LD50 experiment (O, survivors; X, deaths).
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was obtained. The product was a powder stable in air. 
The yield was of 65% with regard to vanadium. IR spec-
trum (KBr; Figure 4) showed the following bands: ν/cm−1 
3,570 (NH), 1,627 (C=O,  co-ordinated), 1,417 (C–N), 
970/842 (O=V=O), 727 δ.  (pyridine ring).
The successful complex formation of TSAG0101 was 
proven in the IR spectrum for the displacement of the carbonyl 
band from its original position in 1,664 cm−1, up to 1,627 cm−1 
(Figure 5). Formation of the complex is evident from 2 bands 
corresponding to the group of dioxovanadate, O=V=O, in 970 
and 842 cm−1. The 1H NMR spectrum ( Figure 5) reflects a 
group of 4 broad bands from 7.6 to 8.2 ppm due to the effect 
of the vanadium that has a quadrupolar nuclear magnetic 
moment and NH
2
 shifted to 8.8 ppm. The solvent signal did 
not show the same broadening, given that no free vanadium 
ions are present in solution. 13C NMR: 5 bands between 122 
and 151 ppm and carbonyl C shifted to 180 ppm (not shown). 
The data discussed above agree with the formula [VVO
2
(OH)
(picolinamide)] and the structure is shown in Figure 5.
Solution stability of TSAg0101
The solution stability of the complex was studied by the 
accumulation of ultraviolet (UV)-spectra in aqueous solution. 
TSAG0101
Cys215
Figure 4 3D-model structure of ligand TSAg0101 and its complex with the target 
structure (PDB code: 1PTU). in particular, cys215 residue interacts with the 
vanadate oxo-oxygen.
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Figure 5 ir spectra of lead candidate TSAg0101 after synthesis. in the insert pane: 1h nMr-spectra of the same compound.
series and Figure 4 displays the structure of TSAG0101 docked 
into the phosphate-binding cleft of the PTP1B target enzyme.
Synthesis and characterization  
of TSAG0101
In the next step, the lead candidate TSAG0101 was 
synthesized and a product with a greenish yellow color 
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Complexes with vanadium in oxidation state +5 display a band 
in the UV region from a charge transfer from ligand to metal, 
whereas those complexes with vanadium in oxidation state +4 
posses 3 bands in the visible region.74,75 Cumulative spectra 
for TSAG0101 in aqueous solution with and without sodium 
citrate are shown in Figure 6. In the first case (Figure 6a), the 
spectrum changed very slowly with time, the charge transfer 
band near 400 nm fade away, and a new band appears in the 
visible region, possibly due to a change in oxidation state of 
the vanadium ion from +5 to +4. The spectrum for the solution 
with citrate behaved in the same way (Figure 6b), indicating 
that citrate did not form a new compound. Citrate is a very 
competitive reducer for metal ions; therefore, the experimental 
compound TSAG0101 is stable with respect to the exchange of 
ligands but it slowly reduces the oxidation state of vanadium 
from +5 to +4. The band observed at 400 nm also could be 
related with the presence of decavanadate. Nevertheless, this 
last species is not the most stable form of free vanadium at 
neutral pH and it has to be introduced from a stock solution 
to be present at low concentration.22
Pancreatic activity
Rat islets responded with a 20-fold increase in insulin secre-
tion to a change from substimulatory to stimulatory glucose 
concentrations. No effects of the test substance on basal- or 
glucose-induced insulin release were observed. There was 
a tendency to inhibit glucose-induced insulin secretion at 
the highest concentrations of test substance, this effect was, 
however, not significant. (Note: further samples with 16.7 mM 
glucose are available but could not be analyzed in this work due 
to inappropriate dilution preparations.) The data also indicate 
an inhibition at the highest concentration because the secretion 
data with a 100 µM test substance are in the range of detection, 
whereas all other values are still above that range (Table 1).
Glucose-induced insulin secretion in static incubation 
is a standard test to determine the metabolic activity of iso-
lated islets. The 20-fold increase of glucose-induced insulin 
 secretion demonstrates that the examined preparations 
 consisted of very active islets. The high secretory activity in 
the presence of 11 mM glucose is a sensitive measure to detect 
a possible influence of the test substance on β-cell metabolism. 
No alteration of basal- or glucose-induced insulin secretion 
was observed excluding a direct effect of the test substance 
on β cells and, therefore, the observed blood glucose lowering 
effect in rats should be an extrapancreatic activity.
LD50 test
Table 2 shows the experimental LD
50
 values determined 
for both, NH
4
VO
3
 and TSAG0101 compounds, using the 
AOT425StatPgm software.
The reliability of the methodology used to obtain LD
50
 
values was confirmed with the value obtained for NH
4
VO
3
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Figure 6 A) cumulative UV-visible spectra of TSAg0101 in 2.5 × 10−4 M aqueous solution. b) cumulative UV-visible spectra of 2.5 × 10−4 M TSAg0101 and 2.5 × 10−4 M 
citrate in aqueous solution.
Table 1 effect of the test substance TSAg0101 on glucose-
induced insulin secretion. Batches of 5 freshly isolated rat islets 
were incubated for 1 hour with glucose and test substance as 
indicated. insulin secretion was measured in ng/mL units. Values 
are means ± SD observed in 3 independent islet preparations
Test substance TSAG0101, μM
0 1 10 100
glucose 2.8 mM 1.1 ± 0.5 1.1 ± 0.7 1.3 ± 0.8 1.4 ± 0.7
glucose 11.1 mM 19.2 ± 0.6 18.4 ± 2.3 19.0 ± 0.7 16.1 ± 2.1
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since it is only slightly above the value reported by Ida et al76 
(55 mg/kg vs 10 mg/kg), which is probably due to experimen-
tal conditions and/or mathematical treatments; however, the 
value lies within the narrow range for all known vanadium 
inorganic salts (10–75 mg/kg) with the exception of sodium 
vanadate (300 mg/kg).
When directly compared, TSAG0101 (LD
50
 412 mg/kg) 
is by far less toxic than caffeine (LD
50
 192 mg/kg) and 
BMOV (220 mg/kg). Besides, being one of the most soluble 
vanadium complexes, this determines that its value of 
nominal LD
50
 becomes comparable with those of soluble 
substances (Table 3). In analogy, our observed LD
50
 value for 
TSAG0101 lies reasonably inside the range of LD
50
 values 
of other organic vanadium compounds that are classified as 
moderately toxic, according to the scales established in the 
literature.
Conclusions
Several vanadium compounds with hypoglycemic activity 
have already been patented.77–81 In particular, an ethyl-
derivative of BMOV entered clinical trials.17,82 In addition, 
vanadium appears as bio-conjugates and in nutritional 
supplements, as well as in cases of illegal doping. In drug 
research, its therapeutic performance is subjected to further 
scrutiny.83,84
As a direct result of our chimerical de novo design, 
TSAG0101 is proposed as a new lead candidate for its struc-
tural simplicity and chemical derivation  potential. Our in 
silico studies led theoretical insight into its  pharmacophore 
pattern and molecular blocking action. The ligand was 
 successfully docked into the phosphate binding site of its 
target, the intracellular PTP1B enzyme. In our in vivo and 
in vitro activity tests, our synthesized compound showed 
less toxicity. The complex was found to be sufficiently 
stable in presence of ubiquitous sodium citrate at the test 
concentration because no changes occurred within 24 hours. 
However, the prodrug function of the experimental com-
pound TSAG0101 cannot be ruled out given the complex 
chemistry of vanadium compounds in aqueous solution. 
This finding could be interpreted against the hypothesis of 
prodrug function which cannot be ruled out for the more 
unstable organic vanadium compounds.46 With regard to the 
patented compounds,77–81 an enhanced pharmacokinetic and 
dynamic drug profile of TSAG0101 can be expected; due to 
its experimental complex stability and theoretical binding 
specificity. In biological assays in rats, TSAG0101 showed 
insulin-like activity (insulin mimesis), also no pancreatic 
component could be observed, ie, its blood glucose lower-
ing effect is of extrapancreatic nature. It is also less toxic 
than caffeine (LD
50
 192 mg/kg) and BMOV (220 mg/kg). 
Because of the present work which extends the known lit-
erature on nonpeptidic insulin mimetics, more studies can be 
conducted in the future to assess the inhibitory concentration 
(IC
50
) activities, as well as extended stability test in aqueous 
solutions under varying concentrations and temperatures by 
NMR and electron paramagnetic resonance spectroscopy. 
Table 2 results of LD50 tests for nh4VO3 and TSAg0101
Test/substance NH4VO3 (ammonium  
vanadate)
TSAG0101
Preliminary estimate  
LD50, mg/kg
175 220
Sigma estimate, mg/kg 0.5 0.5
recommended dose 
progression
2000, 550, 175, 55,  
17.5, 5.5, 1.75
2000, 700, 220, 
70, 22, 7, 2.2, 0.7
essay animal number 8 7
LD50 calculated, mg/kg 55 412
Confident interval to  
95% probability, mg/kg
35.02–155 220–700
Table 3 Solubility data and LD50 values for some vanadium salts and compounds
Vanadium compounds Formula Solubility in water  
g/L 20°C
LD50 mouse, mg/kg References
Vanadium pentoxide; vanadium(V) oxide;  
divanadium pentoxide
V2O5 8 23.4 76
Ammonium vanadate, ammonium metavanadate;  
vanadic acid ammoniacal salt
nh4VO3 58 10 76
55 This work
Vanadyl sulphate; oxovanadium(iV) sulphate VOSO4 Soluble 10 76
Sodium vanadate; sodium metavanadate naVO3 211 (25°c) 388 (75°c) 74.6 85
Sodium orthovanadate; sodium tetraoxovanadate na3VO4 Slightly soluble 300 86
BMOV; bis-maltolateoxovanadate VO(maltol)2 Soluble 220 87
TSAg0101 – Soluble 412 This work
caffeine Soluble 192 88
Sodium cyanide nacn Soluble 6.4 7
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We also expect the new compound will contribute to shed 
some light into the ongoing prodrug discussion either 
identifying or discarding the existence of active specie(s). 
In addition, side chain derivation is thought to improve the 
target selectivity of our nonsubstituted lead candidate which 
we make accessible for future research work.
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